Mohamad Osama, Imai Reiko, Kamada Tadashi, Nitta Yuki, Araki Nobuhito
Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
University of Texas Southwestern Medical Center, Department of Radiation Oncology, Dallas, Texas, USA.
Oncotarget. 2018 May 1;9(33):22976-22985. doi: 10.18632/oncotarget.25165.
Unresectable pediatric osteosarcoma has poor outcomes with conventional treatments.
Twenty-six patients aged 11-20 years (median 16) had inoperable osteosarcoma of the trunk (24 pelvic, 1 mediastinal and 1 paravertebral) without any other lesion at initial examination. There were 22 primary, 1 locally recurrent and 3 metastatic cases. Median CIRT dose was 70.4 Gy RBE (relative biological effectiveness) delivered in 16 fractions. Median follow-up was 32.7 months. Overall survival was 50.0% and 41.7% at 3 and 5 years, respectively. Ten patients survived for more than 5 years (range 5-20.7 years). Local control was 69.9% and 62.9% at 3 and 5 years, respectively and progression-free survival was 34.6% at 3 and 5 years. Only largest tumor diameter correlated with 5-year overall survival and local control. There were 4 grade 3-4 CIRT-related late toxicities, 1 case of bone fracture and no treatment-related mortalities. All patients (except 1) were able to ambulate after CIRT.
CIRT was safe and efficacious in the treatment of inoperable pediatric osteosarcoma with improved local control and overall survival compared to conventional treatments.
We retrospectively reviewed the records of pediatric and adolescent patients who received carbon ion radiotherapy (CIRT) for inoperable osteosarcoma between 1996 and 2014.
不可切除的小儿骨肉瘤采用传统治疗方法预后较差。
26例年龄在11至20岁(中位年龄16岁)的患者患有无法手术切除的躯干骨肉瘤(24例盆腔骨肉瘤、1例纵隔骨肉瘤和1例椎旁骨肉瘤),初诊时无其他病变。其中原发性病例22例、局部复发病例1例、转移病例3例。碳离子放疗(CIRT)的中位剂量为70.4 Gy生物等效剂量(相对生物效应),分16次给予。中位随访时间为32.7个月。3年和5年的总生存率分别为50.0%和41.7%。10例患者存活超过5年(范围为5至20.7年)。3年和5年的局部控制率分别为69.9%和62.9%,无进展生存率在3年和5年时分别为34.6%。仅最大肿瘤直径与5年总生存率和局部控制相关。有4例3 - 4级CIRT相关的晚期毒性反应,1例骨折,无治疗相关死亡病例。所有患者(除1例)在CIRT治疗后能够行走。
与传统治疗相比,CIRT治疗不可切除的小儿骨肉瘤安全有效,可提高局部控制率和总生存率。
我们回顾性分析了1996年至2014年间接受碳离子放疗(CIRT)治疗不可切除骨肉瘤的儿童和青少年患者的记录。